SEC Form 4 · accession 0000899243-16-014985
Oruka Therapeutics, Inc. · ORKA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Bristow
Officer — See Remarks · Director
Period of report
Mar 1, 2016
Accepted (ET)
Mar 2, 2016 · 4:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000907654
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F3,F2 | Mar 1, 2016 | S | 752 | $3.50 | D | 45,334 | D | |
| Common Stock | holding | — | — | — | 19,986 | I | By Investocor Trust as sole Trustee | |
| Common Stock | holding | — | — | — | 25,459 | I | By NFS Custodian for Michael Bristow's IRA |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person for satisfaction of their tax withholding obligation with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Equity Incentive Plan (the "Plan").
- F2Includes (i) remaining 5,952 previously reported shares issued as RSUs under the Plan that vests on 9/17/16, (ii) remaining 4,050 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (iii) 6,871 previously reported shares issued as RSUs under the Plan that vest in three equal annual installments beginning April 2, 2016, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 28,461 previously reported shares of common stock held directly.
- F3The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $3.50 to $3.53. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
Remarks
President and Chief Executive Officer